Featured Research

from universities, journals, and other organizations

Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests

Date:
May 27, 2011
Source:
European League Against Rheumatism
Summary:
Current study designs, assessing the effectiveness of new drugs for the treatment of rheumatoid arthritis (RA), discriminate against patients in the placebo-group, according to a critical appraisal assessing 17 trials. The authors of the study hypothesize that an active comparator group (i.e. current standard of care) should be used in all future new drug study designs as using placebo groups is not ethically acceptable.

Current study designs, assessing the effectiveness of new drugs for the treatment of rheumatoid arthritis (RA), discriminate against patients in the placebo-group, according to a critical appraisal assessing 17 trials, presented at the EULAR 2011 Annual Congress. The authors of the study hypothesize that an active comparator group (i.e. current standard of care) should be used in all future new drug study designs as using placebo groups is not ethically acceptable.

Related Articles


The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their former, ineffective treatment plus placebo.

"According to the Helsinki-Declaration of the World Medical Association*, a placebo-controlled study design is deemed to be ethically acceptable when there is no other effective treatment," said Dr. Juche, Johanniter-Hospital, Treuenbrietzen, Germany. "However, this analysis confirms that patients in the placebo-group are at a disadvantage as they are given no change in medication to reduce their active inflammatory condition or halt disease progression. Our recommendation is that future clinical trials should include an active comparator group to ensure that all patients receive effective treatments to improve their quality of life."

In the analysis, researchers used studies from the European Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for abatacept, golimumab and tocilizumab as samples. The studies chosen had to be placebo controlled at the beginning and state clinical relevant outcome criteria (e.g. DAS28**, ACR20***, Health Assessment Questionnaire and joint erosion scores).

Notes:

*The World Medical Association (WMA) is an organisation promoting the highest possible standards of medical ethics. The WMA provides ethical guidance to physicians through its Declarations, Resolutions and Statements.

**DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is.

***ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint counts.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests." ScienceDaily. ScienceDaily, 27 May 2011. <www.sciencedaily.com/releases/2011/05/110527075909.htm>.
European League Against Rheumatism. (2011, May 27). Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2011/05/110527075909.htm
European League Against Rheumatism. "Use of placebo in rheumatoid arthritis clinical trials may negatively impact patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/05/110527075909.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins